{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:43:25Z","timestamp":1789469005446,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03783-1","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:21:42Z","timestamp":1789464102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evinacumab Across Different Lipid Phenotypes: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Lobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Solis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Patricio","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"3","key":"3783_CR1","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1074\/jbc.M808477200","volume":"284","author":"L Shan","year":"2009","unstructured":"Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem. 2009;284(3):1419\u201324. https:\/\/doi.org\/10.1074\/jbc.M808477200.","journal-title":"J Biol Chem"},{"issue":"5","key":"3783_CR2","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.bbalip.2011.10.010","volume":"1821","author":"F Mattijssen","year":"2012","unstructured":"Mattijssen F, Kersten S. Regulation of triglyceride metabolism by angiopoietin-like proteins. Biochim Biophys Acta. 2012;1821(5):782\u20139. https:\/\/doi.org\/10.1016\/j.bbalip.2011.10.010.","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"3783_CR3","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","volume":"363","author":"K Musunuru","year":"2010","unstructured":"Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med. 2010;363(23):2220\u20137. https:\/\/doi.org\/10.1056\/NEJMoa1002926.","journal-title":"N Engl J Med"},{"issue":"3","key":"3783_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1612790","volume":"377","author":"FE Dewey","year":"2017","unstructured":"Dewey FE, Gusarova V, Dunbar RL, et al. Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease. N Engl J Med. 2017;377(3):211\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1612790.","journal-title":"N Engl J Med"},{"issue":"16","key":"3783_CR5","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2017.02.030","volume":"69","author":"NO Stitziel","year":"2017","unstructured":"Stitziel NO, Khera AV, Wang X, et al. ANGPTL3 deficiency and protection against coronary artery disease. J Am Coll Cardiol. 2017;69(16):2054\u201363. https:\/\/doi.org\/10.1016\/j.jacc.2017.02.030.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3783_CR6","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1093\/eurheartj\/ehad845","volume":"45","author":"\u00c9 Gobeil","year":"2024","unstructured":"Gobeil \u00c9, Bourgault J, Mitchell PL, et al. Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk. Eur Heart J. 2024;45(9):707\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/ehad845.","journal-title":"Eur Heart J"},{"key":"3783_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.2147\/BTT.S500456","volume":"19","author":"B Tomlinson","year":"2025","unstructured":"Tomlinson B, Chan P. Antibody-Based Therapeutics for Hypercholesterolemia. Biologics. 2025;19:631\u201349. https:\/\/doi.org\/10.2147\/BTT.S500456.","journal-title":"Biologics"},{"issue":"7","key":"3783_CR8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res. 2015;56(7):1296\u2013307. https:\/\/doi.org\/10.1194\/jlr.M054882.","journal-title":"J Lipid Res"},{"issue":"8","key":"3783_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27083573","volume":"27","author":"IS Alhomoud","year":"2026","unstructured":"Alhomoud IS. Current and emerging pharmacological therapies for hypertriglyceridemia. Int J Mol Sci. 2026;27(8):3573. https:\/\/doi.org\/10.3390\/ijms27083573.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3783_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmr.2025.100110","volume":"78","author":"AFG Cicero","year":"2026","unstructured":"Cicero AFG, Mahjoubin-Tehran M, Reiner \u017d, Eid AH, Jamialahmadi T, Sahebkar A. From physiopathology to treatment of familial hypercholesterolemia: existing and emerging pharmacotherapies. Pharmacol Rev. 2026;78(2):100110. https:\/\/doi.org\/10.1016\/j.pharmr.2025.100110.","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3783_CR11","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jacl.2026.01.011","volume":"20","author":"Z Ahmad","year":"2026","unstructured":"Ahmad Z, Agarwala A, Cuchel M, et al. Update on familial hypercholesterolemia: an expert clinical consensus from the National Lipid Association. J Clin Lipidol. 2026;20(4):708\u201337. https:\/\/doi.org\/10.1016\/j.jacl.2026.01.011.","journal-title":"J Clin Lipidol"},{"key":"3783_CR12","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.atherosclerosis.2020.10.013","volume":"314","author":"M Harada-Shiba","year":"2020","unstructured":"Harada-Shiba M, Ali S, Gipe DA, et al. A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects. Atherosclerosis. 2020;314:33\u201340. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.10.013.","journal-title":"Atherosclerosis"},{"issue":"6","key":"3783_CR13","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","volume":"140","author":"Z Ahmad","year":"2019","unstructured":"Ahmad Z, Banerjee P, Hamon S, et al. Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia. Circulation. 2019;140(6):470\u201386. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.039107.","journal-title":"Circulation"},{"issue":"2","key":"3783_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","volume":"78","author":"Z Ahmad","year":"2021","unstructured":"Ahmad Z, Pordy R, Rader DJ, et al. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia. J Am Coll Cardiol. 2021;78(2):193\u20135. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.091.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3783_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","volume":"29","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Gaudet D, Ballantyne CM, et al. Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial. Nat Med. 2023;29(3):729\u201337. https:\/\/doi.org\/10.1038\/s41591-023-02222-w.","journal-title":"Nat Med"},{"issue":"5","key":"3783_CR16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.jacl.2025.07.005","volume":"19","author":"RS Rosenson","year":"2025","unstructured":"Rosenson RS, George RT, Sanchez RJ, et al. Efficacy of evinacumab in patients with severe hypertriglyceridemia and a history of severe hypertriglyceridemia-related acute pancreatitis: a phase 2b trial. J Clin Lipidol. 2025;19(5):1223\u201333. https:\/\/doi.org\/10.1016\/j.jacl.2025.07.005.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"3783_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383(8):711\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2004215.","journal-title":"N Engl J Med"},{"issue":"24","key":"3783_CR18","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383(24):2307\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2031049.","journal-title":"N Engl J Med"},{"issue":"11","key":"3783_CR19","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1001\/jamacardio.2023.2921","volume":"8","author":"RS Rosenson","year":"2023","unstructured":"Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia. JAMA Cardiol. 2023;8(11):1070\u20136. https:\/\/doi.org\/10.1001\/jamacardio.2023.2921.","journal-title":"JAMA Cardiol"},{"issue":"9","key":"3783_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2023.100648","volume":"2","author":"FJ Raal","year":"2023","unstructured":"Raal FJ, Rosenson RS, Reeskamp LF, et al. The long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia. JACC Adv. 2023;2(9):100648. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100648.","journal-title":"JACC Adv"},{"issue":"5","key":"3783_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.123.065529","volume":"149","author":"A Wiegman","year":"2024","unstructured":"Wiegman A, Greber-Platzer S, Ali S, et al. Evinacumab for pediatric patients with homozygous familial hypercholesterolemia. Circulation. 2024;149(5):343\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065529.","journal-title":"Circulation"},{"issue":"27","key":"3783_CR22","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1093\/eurheartj\/ehae325","volume":"45","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Greber-Platzer S, Reeskamp LF, et al. Evinacumab in homozygous familial hypercholesterolaemia: long-term safety and efficacy. Eur Heart J. 2024;45(27):2422\u201334. https:\/\/doi.org\/10.1093\/eurheartj\/ehae325.","journal-title":"Eur Heart J"},{"issue":"11","key":"3783_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ph15111389","volume":"15","author":"C Stefanutti","year":"2022","unstructured":"Stefanutti C, Chan DC, Di Giacomo S, Morozzi C, Watts GF. Long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia: real-world clinical experience. Pharmaceuticals (Basel). 2022;15(11):1389. https:\/\/doi.org\/10.3390\/ph15111389.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"3783_CR24","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","volume":"18","author":"C Stefanutti","year":"2024","unstructured":"Stefanutti C, Chan DC, Zeppa G, Watts GF. Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis. J Clin Lipidol. 2024;18(5):e817\u201324. https:\/\/doi.org\/10.1016\/j.jacl.2024.05.006.","journal-title":"J Clin Lipidol"},{"issue":"7","key":"3783_CR25","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1161\/ATVBAHA.124.322364","volume":"45","author":"MJ Wilkinson","year":"2025","unstructured":"Wilkinson MJ, Bijlani P, Davidson MH, et al. Real-world effectiveness and safety of evinacumab in children and adults with homozygous familial hypercholesterolemia: a multisite US perspective-brief report. Arterioscler Thromb Vasc Biol. 2025;45(7):1310\u20135. https:\/\/doi.org\/10.1161\/ATVBAHA.124.322364.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3783_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119234","volume":"406","author":"C Nigmann","year":"2025","unstructured":"Nigmann C, Neyer M, Draxler-Dworzak S, et al. Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C. Atherosclerosis. 2025;406:119234. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2025.119234.","journal-title":"Atherosclerosis"},{"issue":"4","key":"3783_CR27","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jacl.2026.02.007","volume":"20","author":"GG Mombelli","year":"2026","unstructured":"Mombelli GG, Pavanello C, Vicari F, et al. LDL-C target achievement after adding evinacumab in 2 patients with autosomal recessive hypercholesterolemia. J Clin Lipidol. 2026;20(4):833\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2026.02.007.","journal-title":"J Clin Lipidol"},{"issue":"2","key":"3783_CR28","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jacl.2025.11.001","volume":"20","author":"H Tada","year":"2026","unstructured":"Tada H, Takeji Y, Takamura M. Effects of evinacumab on high-density lipoprotein function in patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2026;20(2):428\u201332. https:\/\/doi.org\/10.1016\/j.jacl.2025.11.001.","journal-title":"J Clin Lipidol"},{"key":"3783_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n7","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hofmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n7.","journal-title":"BMJ"},{"key":"3783_CR30","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"28","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;28:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"3783_CR31","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919.","journal-title":"BMJ"},{"issue":"1","key":"3783_CR32","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/XEB.0000000000000202","volume":"18","author":"H Khalil","year":"2020","unstructured":"Khalil H, Bennett M, Godfrey C, McInerney P, Munn Z, Peters M. Evaluation of the JBI scoping reviews methodology by current users. Int J Evid Based Healthc. 2020;18(1):95\u2013100. https:\/\/doi.org\/10.1097\/XEB.0000000000000202.","journal-title":"Int J Evid Based Healthc"},{"key":"3783_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","journal-title":"BMC Med Res Methodol"},{"key":"3783_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metaphor package. J Stat Soft. 2010;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Soft"},{"issue":"13","key":"3783_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12134399","volume":"12","author":"A Gugliucci","year":"2023","unstructured":"Gugliucci A. Triglyceride-rich lipoprotein metabolism: key regulators of their flux. J Clin Med. 2023;12(13):4399.","journal-title":"J Clin Med"},{"key":"3783_CR36","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.2217\/pgs.15.113","volume":"16","author":"PC Santos","year":"2015","unstructured":"Santos PC, Pereira AC. Type of LDLR mutation and the pharmacogenetics of familial hypercholesterolemia treatment. Pharmacogenomics. 2015;16:1743\u201350. https:\/\/doi.org\/10.2217\/pgs.15.113.","journal-title":"Pharmacogenomics"},{"issue":"12","key":"3783_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121648","volume":"12","author":"RAK Srivastava","year":"2023","unstructured":"Srivastava RAK. A review of progress on targeting LDL receptor-dependent and -independent pathways for the treatment of hypercholesterolemia, a major risk factor of ASCVD. Cells. 2023;12(12):1648. https:\/\/doi.org\/10.3390\/cells12121648.","journal-title":"Cells"},{"key":"3783_CR38","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam RC, Mintah IJ, Alexa-Braun CA, et al. Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL processing. J Lipid Res. 2020;61:1271\u201386. https:\/\/doi.org\/10.1194\/jlr.RA120000888.","journal-title":"J Lipid Res"},{"key":"3783_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.atherosclerosis.2021.04.014","volume":"327","author":"LF Reeskamp","year":"2021","unstructured":"Reeskamp LF, Nurmohamed NS, Bom MJ, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13\u20137. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.04.014.","journal-title":"Atherosclerosis"},{"key":"3783_CR40","unstructured":"Evkeeza (evinacumab-dgnb) ANGPTL3 antibody approved in the US for children as young as 1 year old with ultra-rare form of high cholesterol. News release. Regeneron. September 26, 2025. https:\/\/newsroom.regeneron.com\/news-releases\/news-release-details\/evkeezar-evinacumab-dgnb-angptl3-antibody-approved-us-children. Accessed 9 June 2026."},{"key":"3783_CR41","unstructured":"European Medicines Agency (EMA). Evkeeza (evinacumab): EPAR - Medicine overview. Published February 2026. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/evkeeza. Accessed 9 June 2026."},{"key":"3783_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf190","author":"F Mach","year":"2025","unstructured":"Mach F, Koskinas KC, Roeters van Lennep JE, et al. 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2025. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf190.","journal-title":"Eur Heart J"},{"key":"3783_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.11.016","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026. https:\/\/doi.org\/10.1016\/j.jacc.2025.11.016.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3783_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01525-5","volume":"21","author":"RS Patel","year":"2022","unstructured":"Patel RS, Pasea L, Soran H, et al. Elevated plasma triglyceride concentration and risk of adverse clinical outcomes in 1.5 million people: a CALIBER linked electronic health record study. Cardiovasc Diabetol. 2022;21(1):102. https:\/\/doi.org\/10.1186\/s12933-022-01525-5.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"3783_CR45","doi-asserted-by":"publisher","first-page":"14096","DOI":"10.1038\/s41598-018-32337-x","volume":"8","author":"L Kiss","year":"2018","unstructured":"Kiss L, F\u0171r G, M\u00e1trai P, et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci Rep. 2018;8(1):14096. https:\/\/doi.org\/10.1038\/s41598-018-32337-x.","journal-title":"Sci Rep"},{"issue":"2","key":"3783_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.tcm.2019.03.001","volume":"30","author":"V Chyzhyk","year":"2020","unstructured":"Chyzhyk V, Brown AS. Familial chylomicronemia syndrome: a rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis. Trends Cardiovasc Med. 2020;30(2):80\u20135. https:\/\/doi.org\/10.1016\/j.tcm.2019.03.001.","journal-title":"Trends Cardiovasc Med"},{"issue":"9","key":"3783_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.7326\/M19-0203","volume":"170","author":"A Chait","year":"2019","unstructured":"Chait A, Eckel RH. The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment. Ann Intern Med. 2019;170(9):626\u201334. https:\/\/doi.org\/10.7326\/M19-0203.","journal-title":"Ann Intern Med"},{"issue":"6","key":"3783_CR48","doi-asserted-by":"publisher","first-page":"5149","DOI":"10.1111\/dom.70717","volume":"28","author":"MA Elbahloul","year":"2026","unstructured":"Elbahloul MA, Gamal A, Maihoub O, et al. Efficacy and safety of apolipoprotein C-III inhibitors in hypertriglyceridemia: a network meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28(6):5149\u201362. https:\/\/doi.org\/10.1111\/dom.70717.","journal-title":"Diabetes Obes Metab"},{"key":"3783_CR49","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.jacc.2025.02.035","volume":"85","author":"AT Nordestgaard","year":"2025","unstructured":"Nordestgaard AT, Tybj\u00e6rg-Hansen A, Mansbach H, Kersten S, Nordestgaard BG, Rosenson RS. Target populations for novel triglyceride-lowering therapies. J Am Coll Cardiol. 2025;85:1876\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2025.02.035.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"3783_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2026.101020","volume":"67","author":"C Vitali","year":"2026","unstructured":"Vitali C, Banerjee P, Pordy R, Ehmann P, Rosenson RS, Rader DJ. Post-heparin plasma lipase activities in patients with severe hypertriglyceridemia treated with evinacumab. J Lipid Res. 2026;67(4):101020. https:\/\/doi.org\/10.1016\/j.jlr.2026.101020.","journal-title":"J Lipid Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03783-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03783-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:21:45Z","timestamp":1789464105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03783-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":50,"alternative-id":["3783"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03783-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Walter Masson is an Editorial Board member of\n                      Advances in Therapy\n                      , but was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Mara Mansur, Mart\u00edn Lobo, Clara Sol\u00eds, and Juan P Nogueira have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}